Cargando…

Multivariate Exact Discrepancy: A New Tool for PK/PD Model Evaluation

BACKGROUND: Pharmacokinetic models are evaluated using three types of metrics: those based on estimating the typical pharmacokinetic parameters, those based on predicting individual pharmacokinetic parameters and those that compare data and model distributions. In the third groups of metrics, the be...

Descripción completa

Detalles Bibliográficos
Autores principales:	Baklouti, Sarah, Comets, Emmanuelle, Gandia, Peggy, Concordet, Didier
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2023
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10581936/ https://www.ncbi.nlm.nih.gov/pubmed/37717242 http://dx.doi.org/10.1007/s40262-023-01296-6

Ejemplares similares

“De-Shrinking” EBEs: The Solution for Bayesian Therapeutic Drug Monitoring
por: Baklouti, Sarah, et al.
Publicado: (2022)

Hypoalbuminemia and Pharmacokinetics: When the Misunderstanding of a Fundamental Concept Leads to Repeated Errors over Decades
por: Gandia, Peggy, et al.
Publicado: (2023)

Levothyrox(®) New and Old Formulations: Are they Switchable for Millions of Patients?
por: Concordet, Didier, et al.
Publicado: (2019)

The Role of PK/PD Analysis in the Development and Evaluation of Antimicrobials
por: Rodríguez-Gascón, Alicia, et al.
Publicado: (2021)

In vitro dynamic pharmacokinetic/pharmacodynamic(PK/PD) modeling and PK/PD cutoff of cefquinome against Haemophilus parasuis
por: Xiao, Xia, et al.
Publicado: (2015)

Authors’ Reply to Nicolas: “Levothyrox(®) New and Old Formulations: Are they Switchable for Millions of Patients?”
por: Concordet, Didier, et al.
Publicado: (2019)

Population Pharmacokinetic Model of Iohexol in Dogs to Estimate Glomerular Filtration Rate and Optimize Sampling Time
por: Baklouti, Sarah, et al.
Publicado: (2021)

Authors’ Reply to Coste et al.: “Levothyrox(®) New and Old Formulations: Are they Switchable for Millions of Patients?”
por: Concordet, Didier, et al.
Publicado: (2019)

Authors’ Reply to Lechat et al.: “Levothyrox(®) New and Old Formulations: Are they Switchable for Millions of Patients?”
por: Concordet, Didier, et al.
Publicado: (2019)

Authors’ Reply to Yu et al.: “Levothyrox(®) New and Old Formulations: Are They Switchable for Millions of Patients?”
por: Concordet, Didier, et al.
Publicado: (2019)

Authors’ Reply to Castello-Bridoux et al.: “Comment on Levothyrox(®) New and Old Formulations: Are they Switchable for Millions of Patients?”
por: Concordet, Didier, et al.
Publicado: (2019)

Nearly Exact Discrepancy Principle for Low-Count Poisson Image Restoration
por: Bevilacqua, Francesca, et al.
Publicado: (2021)

In vivo Pharmacokinetic and Pharmacodynamic (PK/PD) Modeling and Establishment of the PK/PD Cutoff of Florfenicol Against Pasteurella multocida in Ducks
por: Xiao, Xia, et al.
Publicado: (2021)

Why Were More Than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One?
por: Concordet, Didier, et al.
Publicado: (2019)

Authors’ Reply to Nicolas: “Why Were More than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One?”
por: Concordet, Didier, et al.
Publicado: (2019)

Ceftobiprole: pharmacokinetics and PK/PD profile
por: Azanza Perea, José Ramón, et al.
Publicado: (2019)

PK/PD analysis of trazodone and gabapentin in neuropathic pain rodent models: Translational PK‐PD modeling from nonclinical to clinical development
por: Oggianu, Laura, et al.
Publicado: (2023)

Concerns about pharmacokinetic (PK) and pharmacokinetic-pharmacodynamic (PK-PD) studies in the new therapeutic area of COVID-19 infection
por: Venisse, Nicolas, et al.
Publicado: (2020)

Epidemiological and PK/PD cutoff values determination and PK/PD-based dose assessment of gamithromycin against Haemophilus parasuis in piglets
por: Zhou, Yu-Feng, et al.
Publicado: (2020)

Pharmacokinetic and Pharmacodynamic Evaluation of Marbofloxacin and PK/PD Modeling against Escherichia coli in Pigs
por: Lei, Zhixin, et al.
Publicado: (2017)

Exact order of extreme [Formula: see text] discrepancy of infinite sequences in arbitrary dimension
por: Kritzinger, Ralph, et al.
Publicado: (2022)

Population PK and Semimechanistic PK/PD Modeling and Simulation of Relugolix Effects on Testosterone Suppression in Men with Prostate Cancer
por: Lee, Tien‐Yi, et al.
Publicado: (2022)

Biased computation of probability of target attainment for antimicrobial drugs
por: Toutain, Pierre‐Louis, et al.
Publicado: (2023)

Model‐Informed Drug Development for Antimicrobials: Translational PK and PK/PD Modeling to Predict an Efficacious Human Dose for Apramycin
por: Sou, Tomás, et al.
Publicado: (2020)

PK/PD modeling supports the dose-escalation decision in VIKING
por: Lovern, M, et al.
Publicado: (2010)

The role of population PK–PD modelling in paediatric clinical research
por: De Cock, Roosmarijn F. W., et al.
Publicado: (2010)

Pharmacodynamic Parameters of Pharmacokinetic/Pharmacodynamic (PK/PD) Integration Models
por: Zhang, Longfei, et al.
Publicado: (2022)

The PK/PD Interactions of Doxycycline against Mycoplasma gallisepticum
por: Zhang, Nan, et al.
Publicado: (2016)

Isavuconazole Kinetic Exploration for Clinical Practice
por: Darnaud, Léa, et al.
Publicado: (2018)

Oseltamivir PK/PD Modeling and Simulation to Evaluate Treatment Strategies against Influenza-Pneumococcus Coinfection
por: Boianelli, Alessandro, et al.
Publicado: (2016)

Pharmacokinetics (PK), pharmacodynamics (PD), and PK-PD integration of ceftiofur after a single intravenous, subcutaneous and subcutaneous-LA administration in lactating goats
por: Fernández-Varón, Emilio, et al.
Publicado: (2016)

Meropenem PK/PD Variability and Renal Function: “We Go Together”
por: Angelini, Jacopo, et al.
Publicado: (2023)

1321. Population Pharmacokinetic (PK) and Pharmacokinetic/Pharmacodynamic (PK/PD) Target Attainment Analyses for Dalbavancin in Pediatric Patients
por: Carrothers, Timothy J, et al.
Publicado: (2020)

Prediction of Clinical Irrelevance of PK Differences in Atorvastatin Using PK/PD Models Derived From Literature-Based Meta-Analyses
por: Vargo, R, et al.
Publicado: (2014)

1550. PK-PD Relationship and PK Driver of Efficacy of the Novel Antibacterial Lysin Exebacase (CF-301) in Pre-Clinical Models
por: Ghahramani, Parviz, et al.
Publicado: (2019)

Impact of model misspecification on model-based tests in PK studies with parallel design: real case and simulation studies
por: Guhl, Mélanie, et al.
Publicado: (2022)

Research on the mechanism of drug–drug interaction between salvianolate injection and aspirin based on the metabolic enzyme and PK-PD model: study protocol for a PK-PD trial
por: Zhang, Wantong, et al.
Publicado: (2018)

Pharmacodynamic Evaluation and PK/PD-Based Dose Prediction of Tulathromycin: A Potential New Indication for Streptococcus suis Infection
por: Zhou, Yu-Feng, et al.
Publicado: (2017)

Population PK‐PD Model for Tolerance Evaluation to the p38 MAP Kinase Inhibitor BCT197
por: De Buck, S, et al.
Publicado: (2015)

PK/PD analysis of biapenem in patients undergoing continuous hemodiafiltration
por: Akashita, Gaku, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_v8tvk0sjqgqu16chv4n8opignr